ASA: Door-to-Treatment Time Tied to Survival in Anticoagulation-Linked ICH
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 15, 2024 -- For patients with anticoagulation-associated intracerebral hemorrhage (ICH), earlier door-to-treatment (DTT) time is associated with improved survival, according to a study published online Feb. 9 in JAMA Neurology to coincide with the annual American Stroke Association International Stroke Conference, held from Feb. 7 to 9 in Phoenix.
Kevin N. Sheth, M.D., from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions in a cohort study using data from the American Heart Association Get With The Guidelines-Stroke quality improvement registry. Data were included for 9,492 patients with anticoagulation-associated ICH and documented reversal intervention status.
Overall, 7,469 patients received reversal therapy, including 85.0 percent of the 5,429 patients taking warfarin and 70.2 percent of the 2,069 taking a non-vitamin K antagonist oral anticoagulant. The researchers found that the median onset-to-treatment time was 232 minutes and median DTT time was 82 minutes among the 5,224 patients taking a reversal intervention with documented workflow times. Overall, 27.7 percent had a DTT time of 60 minutes or less, which was associated with reduced mortality and discharge to hospital, but no difference in functional outcome. White race, higher systolic blood pressure, and lower stroke severity were seen in association with DTT time of 60 minutes or less.
"These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca, which partially funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.